Research & Development
R&D Vision
R&D Vision
Extending healthy life expectancy Improving medical access
Medical sophistication Optimization of medical costs
We believe that it is our mission to contribute to ongoing developments in healthcare and human health.
We are working to provide creative new high-value testing and diagnostic technologies to realize personalized medicine optimized for individuals.
R&D Directions
In addition to expanding its operations in existing in vitro diagnostics (IVD) domains, Sysmex is working on initiatives promoting personalized healthcare that responds to individual characteristics and primary care that offers testing nearby patients.
In the area of personalized healthcare, we are developing companion diagnostic drugs related to drug regimens and liquid biopsy technologies* that allow more information to be obtained from the blood.
We are developing testing methods with fewer burdens on patients, miniaturization technology, and aiming at improving operability for achieving primary care strategy.
- Detection of cancer or other diseases by testing blood or other bodily fluids. This type of testing is less invasive than conventional physical biopsies.
Personalized Medicine
Aiming to Select the Best Treatment Methods for Individual Patients
Until now, medical treatment has been disease-based, and a uniform treatment is selected for a given disease. For that reason, diagnostic testing has focused on identifying disease as precisely as possible. However, disease states differ by person, so it is understood that the same treatment method may not be appropriate even for people with the same disease. Nevertheless, selecting the treatment method that is optimal for an individual patient has been extremely difficult.
In recent years, advances in genetic analysis technology have improved precision in identifying diseases and help in evaluating recurrence risk and prognosis.
Where treatment is concerned, the efficacy and side effects of drugs can be predicted when selecting medication, making it possible to select the most optimal treatment for each and every patient. This both reduces the physical burden on the patient and helps control medical costs.
Concept of realizing personalized medicine through testing
Sysmex’s Initiatives
In the past, testing involving specimen sampling (biopsy) was used for direct analysis of the affected tissue, which placed a major burden on the patient. To reduce the burden on patients, Sysmex is promoting R&D activities toward the establishment of new testing technologies for analyzing disease-derived cells, genes, proteins and other elements present in blood and bodily fluids (liquid biopsy).
Principal disease-derived elements present in blood and bodily fluids
R&D Domains
At Sysmex, personnel with expertise in various areas, such as machinery, information and organisms, develop instruments and the reagents used with them.
Sysmex is currently creating technologies to determine abnormally functioning cells in the blood with a high degree of precision and technologies for detecting minute changes in genes. Through these initiatives, we are aiming to realize personalized medicine by liquid biopsy* in cancer and a variety of other disease fields.
- Detection of cancer or other diseases by testing blood or other bodily fluids. This type of testing is less invasive than conventional physical biopsies.
Sysmex’s R&D
Gene measurement technologies
Gene analysis technologies for personalized medicine, such as prediction of onset, recurrence risk and therapeutic efficacy.
Cell measurement technologies
Technologies to detect and analyze the characteristics of rare and abnormal cells in the blood.
Protein measurement technologies
Protein analysis technologies for medical treatment and early detection of infectious diseases, cancer and heart diseases.
